Artes Medical, Inc. (fka ARTEQ)

[Renee]

ARTEQ revoked:

http://www.sec.gov/litigation/admin/2012/34-67430.pdf

[Renee]

ARTEQ SEC Suspension:

http://www.sec.gov/litigation/suspensions/2012/34-67015.pdf

ORDER:

http://www.sec.gov/litigation/suspensions/2012/34-67015-o.pdf

ADMIN Proceeding:

http://www.sec.gov/litigation/admin/2012/34-67016.pdf

[BMiles]

Yep, looking real good.

[WIDESPREAD PANIC]

Hmm, made a pretty decent move here today!

[WIDESPREAD PANIC]

I agree and have been following this since the delisting, but I hate to miss an opportunity!

[mgland]

Better plays out there IMHO. This could be the reason.....
NASDAQ Halts Trading of Artes Medical Inc.
10:17a ET December 8, 2008 (GlobeNewswire)
The NASDAQ Stock Market(r) (Nasdaq:NDAQ) announced that trading was halted in Artes Medical Inc. (Nasdaq:ARTE) today at 9:21:39 a.m., Eastern Time, for "additional information requested" from the company at a last price of $0.03.

Trading will remain halted until Artes Medical Inc. has fully satisfied NASDAQ's request for additional information.

For news and additional information about the company, please contact the company directly or check under the company's symbol using InfoQuotes(sm) on the NASDAQ(r) Web site.

For more information about The NASDAQ Stock Market, visit the NASDAQ Web site at http://www.nasdaq.com.

NDAQO

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: The NASDAQ OMX Group, Inc.

The NASDAQ OMX Group, Inc. Wayne Lee +1.301.978.4850

[WIDESPREAD PANIC]

I might grab a ticket here, bidders biulding, so I think something might happen

[mgland]

Hmmmm. no idea. -e-

[WIDESPREAD PANIC]

Something brewing here???

[mgland]

ARTE. Chapter 7. RIP.

http://www.sec.gov/Archives/edgar/data/1351197/000093639208000753/a50693e8vk.htm

[surf1944]

ArteFill.com Website Launched to Consumers
Monday March 24, 7:30 am ET

SAN DIEGO--(BUSINESS WIRE)--Artes Medical, Inc. (Nasdaq:ARTE - News), a medical technology company whose product ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of “smile line” wrinkles, today reported the launch of its new consumer-oriented website, ArteFill.com. The new website, www.artefill.com/consumer, includes testimonials from patients treated over eight years ago, a before and after photo gallery of ArteFill patients, and a “Discover ArteFill” consumer video educating patients on the use of ArteFill. See accompanying image for an example from our website.

Source: Artes Medical, Inc.

· Example from ArteFill.com consumer website (Graphic: Business Wire). View Multimedia Gallery


“We are excited about the launch of our consumer-oriented ArteFill.com website, highlighting ArteFill as the long-lasting dermal filler treatment for smile lines,” said Diane S. Goostree, President and Chief Executive Officer. “We are pleased that patients are already responding to the variety of new marketing activities we have initiated. We are seeing increased visits to our website with consumers using our ‘Find a Doctor’ section to seek out physicians for their ArteFill treatment. We are building upon these successes to date, as we continue to expand our direct-to-consumer marketing initiatives.”

About ArteFill®

ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds. The unique microspheres in ArteFill are not absorbed by the body and therefore provide the first-of-its-kind permanent support for long-lasting wrinkle correction in one to two treatments.

ArteFill was approved by the FDA in October 2006 based on data from the Company's 12-month controlled, randomized, double-masked, multi-center U.S. clinical trial, which compared outcomes for patients treated with ArteFill with those of patients treated with the leading bovine collagen-based filler. At the 6-month evaluation, which was the primary efficacy evaluation period for the clinical trial, the wrinkle correction in patients treated with ArteFill persisted and showed statistically significant improvement compared to the wrinkle correction in the patients treated with the collagen control, who returned to their pretreatment status. The ArteFill patients were also evaluated one year after treatment, demonstrating continued safety and wrinkle correction.

In December 2007, the Company announced that ArteFill's 5-year safety and efficacy data was disseminated in the peer-reviewed publication Dermatologic Surgery "Filler Issue." This publication addresses the robust, long-term, efficacy and safety profile of ArteFill. This 5-year follow-up study included 145 patients who were treated with ArteFill in the Company's U.S. clinical trial. In addition to demonstrating the safety profile of ArteFill, the study showed statistically significant (p less than 0.001) improvement in patient wrinkle correction five years after the patient's last ArteFill treatment, and a statistically significant (p=0.002) improvement in wrinkle correction at the 5-year point compared to the 6-month evaluation period. As part of the study, physician investigators and patients were asked to provide their assessment of ArteFill treatment. Over 90% of the physician assessments were either "completely successful" or "very successful;" and over 90% of the patient assessments were either "very satisfied" or "satisfied." In March 2007, the Company submitted the data from the study to the FDA for review in order to enhance the product labeling for ArteFill.

An ArteFill Skin Test is required before initial treatment. The most common adverse events associated with ArteFill treatment, similar to those observed with other dermal fillers, are lumpiness, persistent swelling or redness and increased sensitivity at the injection site.

ArteFill is a proprietary formulation comprised of polymethylmethacrylate, or PMMA, microspheres and bovine collagen, and is the only PMMA-based injectable product that has been approved by the FDA for the treatment of facial wrinkles. Artes Medical is the sole manufacturer of ArteFill, which is only available in the United States through Artes Medical, and Artes Medical has not entered into distribution or licensing arrangements with any third party for the distribution or sale of ArteFill, or any other PMMA-based dermal filler, outside the United States.

[surf1944]

4:37PM Artes Medical misses by $0.14, beats on revs; guides FY08 revs in-line (ARTE) 2.22 +0.66 : Reports Q4 (Dec) loss of $0.60 per share, $0.14 worse than the First Call consensus of ($0.46); revenues of $2.4 mln vs the $2.3 mln consensus. Co issues in-line guidance for FY08, sees FY08 revs of $13-16 mln vs. $22.36 mln consensus.

[truthteller2]

Hey anyone know whats going on with this stock should have taken off by now ??????

[surf1944]

ARTE another runner, not really biotech, but I like the thin trading in it.

[surf1944]

Artes Medical's 5-Year Safety and Efficacy Data Presented at the American Academy of Dermatology Conference
Tuesday February 5, 5:32 pm ET


SAN DIEGO--(BUSINESS WIRE)--Artes Medical, Inc. (Nasdaq:ARTE - News), a medical technology company whose product ArteFill® is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of nasolabial fold or "smile line" wrinkles, today announced its participation at the 66th annual meeting of the American Academy of Dermatology (AAD) in San Antonio, Texas at the Henry B. Gonzalez Convention Center. This international conference is the premier venue for dermatologists to learn about new products and dermatologic procedures from experts in their field.

http://biz.yahoo.com/bw/080205/20080205006437.html?.v=1

[surf1944]

Form 8-K for ARTES MEDICAL INC

30-Jan-2008

Entry into a Material Definitive Agreement, Termination of a Material Definitiv


ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
On January 28, 2008, Artes Medical, Inc. (the "Company") entered into a financing arrangement (the "Financing") with Cowen Healthcare Royalty Partners, L.P. ("CHRP") to raise $21.5 million, and up to an additional $1 million in 2009 contingent upon the Company's satisfaction of a net product sales milestone. The Company intends to use the proceeds to expand both its dedicated U.S. sales force and consumer outreach programs and to pay off and terminate its existing credit facility with Comerica Bank. The Financing is expected to close in mid-February.
Under the Revenue Interest Financing and Warrant Purchase Agreement (the "Revenue Agreement"), CHRP will acquire the right to receive a revenue interest on the Company's U.S. net product sales from October 2007 through December 2017 (the "Term"). The Company is required to pay a revenue interest on U.S. net product sales of ArteFill®, any improvements to ArteFill®, any internally developed products and any products in-licensed or purchased by the Company, provided that such improvements, internally developed, in-licensed or purchased products are primarily used for or have an FDA-approved indication in the field of cosmetic, aesthetic or dermatologic procedures. The scope of the products subject to CHRP's revenue interest narrows following the date the cumulative payments the Company makes to CHRP first exceed a specified multiple of the consideration paid by CHRP for the revenue interest.
The revenue interest payable to CHRP on net product sales starts as a high single digit rate and declines to a low single digit rate following the Company's satisfaction of an aggregate net product sales threshold during the Term. In addition to the revenue interest payments, the Company is required to make two lump sum payments of $7.5 million to CHRP, the first in January 2012 and the second in January 2013. Once the cumulative revenue interest and lump sum payments to CHRP reach a specified multiple of the consideration paid by CHRP for the revenue interest, the rate will automatically step down for the balance of the Term. The Company has the right to prepay the revenue interest and lump sum payments without penalty at any time to reach the step-down rate early.
In the event of (i) a change of control of the Company, (ii) a bankruptcy or other insolvency event, or (iii) subject to a cure period, breach of the covenants, agreements, representations or warranties in the Financing documents that results in a material adverse effect on the Company (each a "Put Event"), CHRP has the right to require the Company to repurchase from CHRP its revenue interest at a price in cash which equals the greater of (a) a specified multiple of cumulative payments made by CHRP under the Revenue Agreement less the cumulative payments previously paid by the Company to CHRP under the Revenue Agreement; or (b) the amount which will provide CHRP, when taken together with the payments previously paid under the Revenue Agreement, a specified rate of return. The Revenue Agreement contains certain customary representations, warranties, covenants, agreements and indemnities.
Under the Revenue Agreement, the Company will issue CHRP a warrant to purchase 375,000 shares of the Company's Common Stock, at an exercise price equal to $3.13 per share.

http://biz.yahoo.com/e/080130/arte8-k.html

[surf1944]

Bullish Three White Soldier Pattern (ARTE)

[surf1944]

Taking some ARTE off the table today from $2 purchase(gap filled can anywhere now)

surf

[surf1944]

ArteFill in Head to Head Investigator-Initiated Study to Test Comparative Duration, Safety, and Patient Preference for Dermal Fillers for the Treatment of Smile Lines
Tuesday November 27, 7:30 am ET
Dr. Stacy Smith Launches Study to Compare ArteFill, Radiesse and Restylane, Other Studies Underway

SAN DIEGO--(BUSINESS WIRE)--Artes Medical, Inc. (Nasdaq:ARTE - News), a medical technology company whose product ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of “smile line” wrinkles, today announced that Dr. Stacy Smith, a leading San Diego based dermatologist, is conducting a head-to-head clinical study comparison of dermal fillers – ArteFill, Radiesse and Restylane. This 24 patient study will evaluate nasolabial fold, or smile line wrinkle, correction over a two year period.

Stacy R. Smith, MD, President, Therapeutics Clinical Research, Assistant Clinical Professor of Dermatology, University of California San Diego, Division of Dermatology, is conducting this “split-face” study whereby patients will receive ArteFill on one side of their face and will receive a temporary dermal filler, either Restylane or Radiesse on the other. Every three months, photographs will be taken to allow a blinded evaluation of the patients’ degree of wrinkle correction. Patients will also be asked to provide their assessment of wrinkle correction and level of satisfaction with the treatment on each side of their face. These patients will be followed for a total of two years and the possibility of announcing interim results will be assessed by Dr. Smith throughout the study. When one of the smile lines on the “temporary filler treated” side of their face returns to baseline, the patient will have the option to cross over and receive ArteFill.

Dr. Smith expects to enroll 24 patients by the end of March 2008. A patient satisfaction survey along with patient photos of the results are part of the study protocol. After study completion, these findings will be submitted and are expected to be published in a peer reviewed dermatology journal.

For more information on Dr. Smith or his study, please call [phone] or visit www.therapeuticsresearch.com. Dr. Smith received a research grant from Artes Medical, Inc. to conduct this study.

Artes Medical is evaluating and anticipates awarding clinical research grants to other investigators for additional ArteFill studies. Press releases issued by physicians conducting clinical studies with research grants from Artes Medical will be posted on the Investor Relations section of our website at www.artesmedical.com under “Investigator-Initiated Studies.”

http://biz.yahoo.com/bw/071127/20071127005257.html?.v=1

[surf1944]

Leading Beverly Hills Facial Plastic Surgeon Launches Study to Evaluate ArteFill for ''Non-Surgical Nose Jobs''

Leading Beverly Hills, CA – based facial plastic surgeon, Dr. John Joseph announced today he is conducting a study with the use of ArteFill to reshape nasal contour deformities without the need for conventional surgery.

John H. Joseph, MD, Assistant Clinical Professor, Department of Head and Neck Surgery, University of California, Los Angeles, is conducting this study to evaluate ArteFill for the cosmetic improvement of nasal contour deformities which are naturally occurring, or a result of a past rhinoplasty surgery or trauma.

Dr. Joseph expects to enroll 20 patients by the end of March 2008. A patient satisfaction survey along with patient photos of the results and clinical grading are part of the current study protocol. These patients will be followed for one year after ArteFill treatment. After study completion, these findings will be submitted and are expected to be published in a peer reviewed plastic surgery journal.

According to the American Society for Aesthetic Plastic Surgery (ASAPS) there were approximately 300,000 rhinoplasties performed in 2006. Published studies indicate that approximately 10 percent of rhinoplasties need to be re-done or fine-tuned.

“Since ArteFill is a long-lasting tissue bulking filler, I have had success sculpting the nose and it seems clear that only a non-resorbable filler like ArteFill, can provide the long-lasting repair and treatment that my patients are seeking. It is a good alternative for those not wanting a second invasive surgery or even as an alternative to an initial surgery. I have already incorporated ArteFill in my medical practice for smile lines and I can now document the use of ArteFill for rhinoplasty revisions and other uses,” said Dr. Joseph.

Dr. Joseph received a research grant from Artes Medical, Inc. (NASDAQ:ARTE) to conduct this study. For more information on Dr. Joseph at Brighton Medical Corporation or his study call [phone] or visit www.drjohnjoseph.com.

For Brighton Medical Corporation
John H. Joseph, MD, 310-859-7193
www.drjohnjoseph.com

Source: Business Wire (November 6, 2007 - 7:30 AM EST)

News by QuoteMedia
www.quotemedia.com

[surf1944]

Artes Medical's 5-Year Safety and Efficacy Data Presented at the American Society of Plastic Surgeons (ASPS) Conference

-- ArteFill® live injection demonstration at plastic surgery conference --

Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced its participation at the recent American Society of Plastic Surgeons (ASPS) Conference on October 27-30, 2007 at the Baltimore Convention Center, in Baltimore, Maryland. This conference is a venue for plastic and reconstructive surgeons to learn about new products, procedures and cutting-edge technology from experts in their field. In the quest to eradicate the signs of aging, cosmetic plastic surgery patients continue to demand better, long lasting results with no downtime.

ArteFill was presented during the “Facial Rejuvenation Through the Combined Use of Dermal Fillers and Injectables” course. This scientific session included an update on the long-term safety and efficacy of ArteFill and a live injection demonstration by Steven R. Cohen, MD, Clinical Professor, Division of Plastic Surgery, University of California, San Diego School of Medicine.

“Dr. Cohen’s live patient injection demonstrated the ease of use, excellent flow characteristics and the immediate natural look and feel of results that can be achieved with ArteFill. We often also have patients from our 5-year clinical trial attend our injection training sessions so physicians can observe the long-lasting effects, and the continuing attractive look and feel of the implant as the face ages naturally, over a number of years. This conference was an opportune setting for plastic surgeons to learn about ArteFill’s long lasting results for the correction of smile lines,” said Diane S. Goostree, President and Chief Executive Officer.

About ArteFill®

ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds. The unique microspheres in ArteFill are not absorbed by the body and therefore provide the first-of-its-kind permanent support for long-lasting wrinkle correction in one to two treatments.

ArteFill was approved by the FDA in October 2006 based on data from the Company’s 12-month controlled, randomized, double-masked, multi-center U.S. clinical trial, which compared outcomes for patients treated with ArteFill with those of patients treated with the leading bovine collagen-based filler. At the 6-month evaluation, which was the primary efficacy evaluation period for the clinical trial, the wrinkle correction in patients treated with ArteFill persisted and showed statistically significant improvement compared to the wrinkle correction in the patients treated with the collagen control, who returned to their pretreatment status. The ArteFill patients were also evaluated one year after treatment, demonstrating continued safety and wrinkle correction.

In February 2007, the Company announced it completed a 5-year follow-up study of 145 patients who were treated with ArteFill in the Company's U.S. clinical trial. In addition to demonstrating the safety profile of ArteFill, the study showed statistically significant (p<0.001) improvement in patient wrinkle correction five years after the patient's last ArteFill treatment, and a statistically significant (p=0.002) improvement in wrinkle correction at the 5-year point compared to the 6-month evaluation period. As part of the study, physician investigators and patients were asked to provide their assessment of ArteFill treatment. Over 90% of the physician assessments were either "completely successful" or "very successful;" and over 90% of the patient assessments were either "very satisfied" or "satisfied." In March 2007, the Company submitted the data from the study to the FDA for review in order to enhance the product labeling for ArteFill.

An ArteFill Skin Test is required before initial treatment. The most common adverse events associated with ArteFill treatment, similar to those observed with other dermal fillers, are lumpiness, persistent swelling or redness and increased sensitivity at the injection site.

ArteFill is a proprietary formulation comprised of polymethylmethacrylate, or PMMA, microspheres and bovine collagen, and is the only PMMA-based injectable product that has been approved by the FDA for the treatment of facial wrinkles. Artes Medical is the sole manufacturer of ArteFill, which is only available in the United States through Artes Medical, and Artes Medical has not entered into distribution or licensing arrangements with any third party for the distribution or sale of ArteFill, or any other PMMA-based dermal filler outside the United States.

About Artes Medical, Inc.

Artes Medical is a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for the dermatology and plastic surgery markets. The Company’s initial product, ArteFill, is being marketed to men and women as a treatment option for the correction of nasolabial folds. There were approximately two million dermal filler procedures in the U.S. in 2006, an increase of 25% over the prior year, according to the American Society for Aesthetic Plastic Surgery, or ASAPS. Additional information about Artes Medical and ArteFill is available at www.artesmedical.com and www.artefill.com.

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company’s current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, which include the Company’s history of net losses, its reliance on its sole FDA-approved product, ArteFill, its limited experience in commercializing ArteFill, and its future receipt of FDA approval to enhance the product label for ArteFill to extend the efficacy period of ArteFill beyond six months, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. A more extensive set of risks and uncertainties is set forth in the Company’s SEC filings available at www.sec.gov. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Artes Medical® and ArteFill® are registered trademarks of Artes Medical, Inc.

Investor Relations:
Artes Medical, Inc.
Cheryl Monblatt Allen, 858-550-9999
[e-mail]
or
Corporate Media:
Schwartz Communications, Inc.
Thea Lavin, 415-512-0770
[e-mail]


Source: Business Wire (October 31, 2007 - 7:34 AM EDT)

News by QuoteMedia
www.quotemedia.com

[surf1944]

Dr. Stacy Smith Launches Study to Test Duration, Safety and Patient Preference for Dermal Fillers for the Treatment of Smile Lines
Monday October 29, 4:45 pm ET
Study Compares ArteFill, Radiesse and Restylane

SAN DIEGO--(BUSINESS WIRE)--Leading San Diego, CA – based dermatologist Dr. Stacy Smith announced today he is conducting a head-to-head clinical study comparison of dermal fillers – ArteFill, Radiesse and Restylane. This 24 patient study will evaluate nasolabial fold, or smile line wrinkle correction over a two year period.

Stacy R. Smith, MD, President, Therapeutics Clinical Research, Assistant Clinical Professor of Dermatology, University of California San Diego, Division of Dermatology, is conducting this “split-face” study whereby patients will receive ArteFill on one side of their face and will receive a temporary dermal filler, either Restylane or Radiesse on the other. Every three months, photographs will be taken to allow a blinded evaluation of the patients’ level of wrinkle correction. Patients will also be asked to provide their assessment of wrinkle correction and level of satisfaction with the treatment on each side of their face. These patients will be followed for a total of two years and the possibility of announcing interim results will be assessed throughout the study. When one of the smile lines returns to baseline, the patient will have the option to cross over and receive ArteFill on the “temporary filler treated” side of their face for full wrinkle correction.

Dr. Smith expects to enroll 24 patients by the end of March 2008. A patient satisfaction survey along with patient photos of the results are part of the study protocol. After study completion, these findings will be submitted and are expected to be published in a peer reviewed dermatology journal.

“I am looking forward to conducting this study to provide valuable information comparing the temporary fillers with ArteFill. ArteFill has shown persistence up to 5 years in recently published results. A direct comparison will better illuminate the differences in performance and patient preference between ArteFill and the temporary fillers. Both physicians and consumers need this kind of information to make better informed decisions regarding their choice of a dermal filler,” said Dr. Smith.

For more information on Dr. Smith or his study, please call [[phone] or visit www.therapeuticsresearch.com]

Dr. Smith received a research grant from Artes Medical, Inc. (NASDAQ:ARTE - News) to conduct this study.


Contact:

Schwartz Communications
Erin Walsh or Thea Lavin, 415-512-0770

[surf1944]

Improving Chaikin Money Flow (ARTE)

[surf1944]

Artes Medical to Present at Roth Capital and Oppenheimer Investor Conferences

Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced it will present at the Roth Capital 2007 New York Conference on Wednesday, September 5, 2007 at 9:30 a.m., Eastern Time, at The Westin New York Times Square.

A live audio webcast of the presentation at Roth Capital will be accessible through Artes Medical’s investor relations web site at http://ir.artesmedical.com. An archived edition of the presentation will be available later that day and archived for 180 days.

Artes Medical also will present at the Oppenheimer Consumer Conference on Monday, September 10, 2007 at 8:40 a.m., Eastern Time, at the Jolly Hotel Madison Towers in New York City.

Diane S. Goostree, President and Chief Executive Officer, will provide a corporate overview of the Company at both of these investor conferences.

Artes Medical's news releases and other information about the Company and its FDA-approved product, ArteFill, are available on its web site at www.artesmedical.com.

About ArteFill®

ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds. The unique microspheres in ArteFill are not absorbed by the body and therefore provide the first-of-its-kind permanent support for long-lasting wrinkle correction in one to two treatments.

ArteFill was approved by the FDA in October 2006 based on data from the Company’s 12-month controlled, randomized, double-masked, multi-center U.S. clinical trial, which compared outcomes for patients treated with ArteFill with those of patients treated with the leading bovine collagen-based filler. At the 6-month evaluation, which was the primary efficacy evaluation period for the clinical trial, the wrinkle correction in patients treated with ArteFill persisted and showed statistically significant improvement compared to the wrinkle correction in the patients treated with the collagen control, who returned to their pretreatment status. The ArteFill patients were also evaluated one year after treatment, demonstrating continued safety and wrinkle correction.

In February 2007, the Company announced it completed a 5-year follow-up study of 145 patients who were treated with ArteFill in the Company's U.S. clinical trial.

In addition to demonstrating the safety profile of ArteFill, the study showed statistically significant (p less than 0.001) improvement in patient wrinkle correction five years after the patient's last ArteFill treatment, and a statistically significant (p equal to 0.002) improvement in wrinkle correction at the 5-year point compared to the 6-month evaluation period. As part of the study, physician investigators and patients were asked to provide their assessment of ArteFill treatment. Over 90% of the physician assessments were either "completely successful" or "very successful;" and over 90% of the patient assessments were either "very satisfied" or "satisfied." In March 2007, the Company submitted the data from the study to the FDA for review in order to enhance the product labeling for ArteFill.

An ArteFill Skin Test is required before initial treatment. The most common adverse events associated with ArteFill treatment, similar to those observed with other dermal fillers, are lumpiness, persistent swelling or redness and increased sensitivity at the injection site.

ArteFill is a proprietary formulation comprised of polymethylmethacrylate, or PMMA, microspheres and bovine collagen, and is the only PMMA-based injectable product that has been approved by the FDA for the treatment of facial wrinkles. Artes Medical is the sole manufacturer of ArteFill, which is only available in the United States through our Company, and we have not entered into distribution or licensing arrangements with any third party for the distribution or sale of ArteFill outside the United States.

[surf1944]

Oversold with an Improving RSI (ARTE)